Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508907 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
A Phase 4 study of Hepatitis C and Kidney Transplant; Complications, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04508907: Active Phase 4 study of Hepatitis C and Kidney Transplant; Complications, sponsored by Mayo Clinic.
NCT04508907 is a Phase 4 study of Hepatitis C and Kidney Transplant; Complications that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04508907, a Phase 4 study of Hepatitis C and Kidney Transplant; Complications, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
Primary Outcome
The study will assess the percentage of patient who will not become HCV viremic using this preemptive treatment protocol.
Conditions Studied
Interventions
- DRUG Mavyret
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 4 |
What the registry record for NCT04508907 still lists
NCT04508907 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Mavyret is the first listed.
NCT04508907 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04508907 about?
NCT04508907 is a clinical study titled "A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients". This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
What is the current status of trial NCT04508907?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-09-10. Estimated completion is 2026-11-01.
What conditions does trial NCT04508907 study?
This clinical trial studies the following conditions: Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection.
What interventions are being tested in trial NCT04508907?
The interventions under investigation include: Mavyret (DRUG).
Who is sponsoring clinical trial NCT04508907?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04508907 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04508907's enrollment target sits among peer trials
200 42nd of 106 higher than 64 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI